FDA Draft Guidance Would Require Abuse Deterrence For Generic Opioid Drugs
The FDA said generic versions of opioids should be no less abuse-deterrent than brand-name opioid drugs. The agency said the draft guidance recommends that generic drug makers conduct studies to demonstrate abuse deterrence.
The FDA said a public meeting will be held later this year to discuss the draft guidance.
Opioids can be abused by...
To view the full article, register now.